With the promise of billions of dollars in payouts from corporate partners, OncoMed Pharmaceuticals Inc. was riding high — so much so that CEO Paul Hastings two years ago said, "It puts us in a nice space. We talk to investors but we don't need to spend time talking to people to raise money."
It wasn't just bravado or a case of Hastings strutting his Redwood City company's financial stuff: If OncoMed (NASDAQ: OMED) was successful at key points in its clinical trials of cancer stem cell treatments…
With the promise of billions of dollars in payouts from corporate partners, OncoMed Pharmaceuticals Inc. was riding high — so much so that CEO Paul Hastings two years ago said, "It puts us in a nice space. We talk to investors but we don't need to spend time talking to people to raise money."
It wasn't just bravado or a case of Hastings strutting his Redwood City company's financial stuff: If OncoMed (NASDAQ: OMED) was successful at key points in its clinical trials of cancer stem cell treatments…